Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul J. Hastings
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Beta
- 0.97
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -3.76
Financials
Revenue
$0.00-100.0%Net Income
$-33.33MEBITDA
$-33.72MFree Cash Flow
$-27.08MEPS (diluted)
$-0.45Shares Outstanding (diluted)
74.64M+730.9%Operating Expenses
$35.78MCash & Debt
$156.61MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-104.08M | $-1.41 |
| 2024 | $0.00 | $-108.79M | $-1.60 |
| 2023 | $0.00 | $-117.50M | $-2.40 |
| 2022 | $0.00 | $-113.84M | $-2.61 |
| 2021 | $0.00 | $-86.08M | $-2.62 |
| 2020 | $0.00 | $-91.36M | $-1.59 |
| 2019 | $115.4K | $-21.08M | $-2.55 |
| 2018 | $6.55M | $-274.5K | $-0.01 |
Valuation
NKTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·11d ago·Negative
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host disease (GvHD) across 40 patients treated across five indications in the Ntrust program. No deaths and no treatment discontinuations due to adverse events.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief Medical Officer and Head of Research & Development Nadir Mahmood - President and Principal Accounting & Financial Officer Conference Call Participants Gil Blum - Needham & Company, LLC, Research Divi…
View source ↗ - Newsglobenewswire.com·16d ago·Negative
… Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis be…
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance Nkarta NASDAQ: NKTX said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety.
View source ↗ - Newsglobenewswire.com·73d ago·Negative
Nkarta to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.
View source ↗
Earnings
Wed, Mar 24(in 4 months)
Consensus estimate $-0.45 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.45 vs $-0.40miss
- Mon, Aug 10$-0.54 vs $-0.36miss
- Tue, May 12$-0.37 vs $-0.39beat
- Wed, Mar 25$-0.37 vs $-0.32miss
- Mon, Nov 10$-0.29 vs $-0.32beat
- Tue, Aug 12$-0.31 vs $-0.37beat
Estimates and results for NKTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NKTX officers and directors.
- Bought
- $50.0m
- Sold
- $603k
4 trades
23 trades
- Hastings Paul Jsold
- Hastings Paul Jsold
- Mahmood Nadirsold
- Hastings Paul Jsold
- Shook Davidsold
- Levin Alyssasold
- Brandenberger Ralphsold
- Hastings Paul Jsold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NKTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
